Compare TENX & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | IPWR |
|---|---|---|
| Founded | 1967 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 65.4M |
| IPO Year | 2001 | 2013 |
| Metric | TENX | IPWR |
|---|---|---|
| Price | $1.49 | $3.01 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.56 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 137.8K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,550.55 |
| Revenue Next Year | N/A | $600.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $2.62 |
| 52 Week High | $19.40 | $9.30 |
| Indicator | TENX | IPWR |
|---|---|---|
| Relative Strength Index (RSI) | 28.27 | 26.60 |
| Support Level | $1.31 | $2.63 |
| Resistance Level | $2.00 | $3.33 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 18.77 | 5.65 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.